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S U M M A R Y
Epstein-Barr Virus (EBV) infection can lead to infectious mononucleosis syndrome with the typical
symptoms of fever, pharyngitis, and lymphadenopathy. Self-limited mild to moderate elevation of liver
enzymes and hepatosplenomegaly are common. However, cholecystitis is not usually considered part of
a primary EBV infection and ultrasound scan (USS) of the liver and gallbladder is not routinely
performed. Acute acalculous cholecystitis (AAC) caused by etiologies other than primary EBV infection is
often associated with severe illness and antibiotic treatment and surgery may be needed. We present a
case with primary EBV infection and AAC and a literature review.
Our patient was a 34-year-old woman with clinical, biochemical and serological signs of primary EBV
infection (lymphocytes 7.6  10^9/l, monocytes 2.6  10^9/l, positive early antigen IgM test and
14 days later positive early antigen IgG test). During admission, increasing liver function tests indicated
cholestasis (alanine aminotransferase 61 U/l, alkaline phosphatase 429 U/l and bilirubin 42 mmol/l). USS
revealed a thickened gallbladder wall indicating cholecystitis but no calculus. All other microbiological
tests were negative. The literature search identiﬁed 26 cases with AAC and acute EBV infection; 25 cases
involved females. Sore throat was not predominant (six reported this), and all cases experienced
gastrointestinal symptoms. Our and previous published cases were not severely ill and recovered
without surgical drainage.
In conclusion primary EBV infection should be considered in cases of AAC, especially in young women.
In cases associated with EBV infection neither administration of antibiotics nor surgical drainage may be
indicated.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Epstein Barr Virus (EBV) is a herpes virus prevalent in humans
throughout the world. EBV resides in memory B-cells and is
transmitted through saliva often from asymptomatic individuals.
In developing countries children acquire primary EBV infection
early when the infection is often asymptomatic. In developed
countries primary EBV infection typically occurs in adolescence or
early adulthood when the infection is more often symptomatic. At
this age EBV infection may cause infectious mononucleosis (IM)Abbreviations: EBV, Epstein-Barr virus; USS, Ultrasound scan; AAC, Acute acalcu-
lous cholecystitis; EA, Early antigen; EBNA, EBV nuclear antigen.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).syndrome characterised by three main symptoms: fever, pharyn-
gitis, and lymphadenopathy. Mildly to moderately elevated
transaminases and alkaline phosphatase and hepatosplenomegaly
are seen in most cases.1,2 However, EBV is usually not considered to
be causing cholecystitis. Acute acalculous cholecystitis (AAC) is
known to occur in critically ill patients with severe infections or
injuries.3 Cholecystectomy or more recently percutaneous drain-
age has been the standard of care in AAC.3We present a case of EBV
infection with AAC and compare our case with previously
described cases. We aim to increase awareness of possible EBV
infection in AAC in order to avoid unnecessary surgery and use of
antibiotic treatment in future cases.
2. Case report
A 34-year-old female was admitted with suspected malaria due
to a febrile illness one month after a short travel to Burkina Faso inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Inﬂammatory markers (A) and liver biochemical markers (B) in the present case of AAC in primary EBV infection.
A) More than 50% of leukocytes were lymphocytes, ___ line below antibiotics indicates time period administered.
Figure 2. Ultrasound scan of liver and gallbladder showing thickened gallbladder
wall (11.3 mm).
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general malaise, headache, dizziness, nausea, muscle aches, and
fever during a period of one week. Initially, the patient had joint
pain and at the time of admission facial pain (above the sinuses)
and slight precordial heaviness. There had been an alternating
bowel pattern since returning from Africa. During hospitalisation,
the patient suffered from constipation, which she stated was
common when daily routines changed.
The patient had no history of disease except for exercise-
induced asthma; her mother had type 2 diabetes and breast cancer.
Mosquitoes bit her during her stay in Africa but she took malaria
prophylaxis as prescribed (atovaquon/proguanil). She stayed in a
city and was in contact with locals when meeting with their
adopted child. Further an outbreak of parvovirus B19 infection was
suspected in her other child´s kindergarten in Denmark.
The patient did not appear severely ill. Vital signs: Temperature
37.1 (later 39) 8C, Glasgow Coma Score 15, blood pressure 106/61,
heart rate 65 per minute, and oxygen saturation 100%. Body weight
48 kg. Periorbital oedema was observed. A 3x2 cm tender glandule
was palpated at her left angulus mandibulae. Three days after
admission general lymphadenopathy and intermittent abdominal
pain developed.
Laboratory investigations on admission: CRP 42 (<8) mg/l, ESR
12 (2-20) mm, leukocytes 5.6 (3.5-10) x10^9, lymphocytes 3.2
(1.3-3.5) x10^9, monocytes 0.5 (0.2-0.7) x10^9. Inﬂammatory
markers reached a maximum on day ﬁve of admission: CRP 65 mg/l,
leukocytes 12.6 x10^9, lymphocytes 7.6 x10^9 and monocytes
2.6 x10^9 (Figure 1A). Liver enzymes were normal on admission
except for lactate dehydrogenase (LDH) of 445 (105-205) U/l;
bilirubin, alkaline phosphatase (ALP) and prothrombin time (PT)
(coagulation factor II, VII, X) were normal. On day ﬁve LDH was
572 U/l, alanine aminotransferase (ALT) 61 (10-45) U/l, bilirubin 42
(5-25) mmol/l, ALP 429 (35-105) U/l, PT 0.87 (0.7-1.30), (Figure 1B).
During admission slight hemolysis developed with a drop in
hemoglobin from 7.1 to 6.4 (7.1-9.3) mmol/l and haptoglobin below
0.17 (0.35-1.85) g/l on day seven. Platelets were low on the day of
admission (146x10^9) and rose to normal.
Serology performed on day two after admission revealed
primary EBV infection: IgM EBV-EA positive, IgG EBV-EA negative,
IgG-EBNA negative. On day 16 IgM EBV-EA positive, IgG EBV-EA
positive, IgG-EBNA negative.
Inﬂuenza A and B RNA in nasal secretion and CMV antigen in
blood were negative. No malaria parasites were found in three
malaria smears. Other serology performed: CMV IgM negative/IgGpositive; Coxiella burnetti negative; parvovirus IgM negative/IgG
positive; toxoplasmosis IgM negative/IgG negative, anti-hepatitis
A IgM negative, HBsAg negative, anti-HBc IgM negative, anti-
hepatitis C negative. HIV 1+2 antibody negative. C-ANCA IgG
negative, P-ANCA IgG negative, ANA negative. Blood cultures were
negative. In a urine sample and in eight faecal samples no
pathogenic bacteria or parasites were recovered.
At admission a chest X-ray showed a ﬂat right side diaphragm
and on day six of admission a discrete basal inﬁltrate and pleural
effusion on the right side of her thorax had evolved. A USS of the
upper abdomen on day four showed a thickened and oedematous
gallbladder wall (11.3 mm) and small amount of ascites (Figure 2).
PET-CT on day eight showed FDG uptake in multiple glands in the
neck, axillae, groin and pulmonary hili and diffuse FDG uptake in
the spleen. Furthermore, a cystic change with calciﬁcation in the
upper pole of the spleen was noted.
The surgeon concluded the abdomen was not particularly
tender and recommended careful monitoring of the situation. On
indication AAC, in a patient with recent stay in Burkina Faso,
Salmonella typhi infection was suspected and intravenous
Ceftriaxone was started on day ﬁve. Due to the basal lung inﬁltrate
intravenous antibiotics were followed up by oral moxiﬂoxacin for a
total of 10 days. The patient was discharged on day nine. She
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well when seen in the outpatient clinic ﬁve weeks after hospital
discharge. The previously found cyst in the spleen was controlled
six months after discharge and was concluded to be non-
pathogenic. Echincoccus antibodies were negative.
Written informed consent was obtained from the patient for
publication of this case report.
3. Description of and comparison with previously reported
cases
3.1. Methods
We searched the PubMed database using the search words
‘‘Epstein-Barr virus’’ and ‘‘acalculous cholecystitis’’, explored the
references in the papers from the search result, and compared our
case with previously published case reports.
When signs or symptoms were not explicitly described in the
case report, it was considered not present (Table 1). Normal
bilirubin values were missing in some reports and we considered
total bilirubin levels above or equal to 21 mmol/L or 1.2 mg/dL to
be above normal. Thickening of the gallbladder wall is the most
reliable criterion for AAC.4
3.2. Results
The search resulted in 26 reported cases of AAC (Table 1).5–27 All
were reported in recent years (later than 2003). Twenty-four of the
26 reported cases and the present case fulﬁlled the criterion of
gallbladder wall thickness above 3.5 mm. In the two cases without
measurement of the gallbladder wall diffuse oedema and marked
thickened gall bladder wall respectively were described. All case
reports were female patients except one. Age of the patients ranged
between 4 and 53 years and cases were primarily reported from
Europe: Europe (and Turkey) 19 cases, USA and Canada 3 cases, and
South East Asia 4 cases. No previous cases were reported from
Scandinavian countries.
Clinical symptoms were not always the classic symptoms of
primary EBV at admission in the present or previous cases. Only six
reported sore throat. However, 22 were referred with abdominal
pain and all reported abdominal pain during admission. Pharyngi-
tis was observed in 16, lymphadenopathy at admission in 16 cases,
and hepatosplenomegaly in 12 cases. Five patients (including our
patient) developed lymphadenopathy during hospital stay or had
lymphadenopathy detected in a CT scan. All but three case reports
documented positive Murphy’s sign at USS (18 cases) or right
upper quadrant tenderness at clinical examination (six cases
including the present case). ALT was elevated in 25 cases (two
cases had missing information). Hyperbilirubinaemia was present
in 19 patients (3 missing information) and increased ALP levels
were reported in 22 patients (ﬁve missing information).
No patients had an elevated CRP level suggesting bacterial
secondary infection. Antibiotics were administered in 17 of
27 patients (two missing information). Broad spectrum antibiotics
were used e.g. ceftazixim, tobramycin, metronidazole;5 cefotax-
ime;8 amoxicillin-clavulanic acid;9 ceftazidime, gentamycin,
metronidazole.11 A more severe course of illness was not described
in the eight patients who did not receive antibiotics.6,7,10,12,19–21,23
In the reports on these eight patients we found no symptoms or
clinical signs which distinguished them from patients who were
treated with antibiotics (six of the eight patients had all signs and
symptoms) (Table 1). Furthermore, patients who were not treated
with antibiotics had similar levels of cholestatic markers,
leucocytes, and CRP values compared with those who were treated
with antibiotics. The eight patients who did not receive antibiotics
had a mean gallbladder wall thickness of 9.3 (4.2-14) mm; patientsreceiving antibiotics had a mean gallbladder wall thickness of 9.4
(4.6-16) mm. Antibiotics did not reduce length of hospitalisation
(6 to 13 days in patients who did not receive antibiotics vs. 5 to
19 days in patients who received antibiotics) (Table 1).
One immunosuppressed patient underwent laparoscopic cho-
lecystectomy. Postoperative pleuropneumonia, haemolytic anae-
mia and no positive bacteria cultures were described in this case.
The patient was treated with corticosteroids due to complicated
EBV infection. It was not obvious from the report whether surgery
was believed to change the course of illness. The patient improved
and was discharged on day 19.11 All other patients recovered
without surgery even though one was suspected to have
perforation of the gallbladder.14 All patients fully recovered during
the following weeks or months (in less than 5 months).5–27
4. Discussion
We present the ﬁrst reported case of primary EBV infection
complicated by AAC in Scandinavia. Symptoms and ﬁndings were
comparable with 26 previously described cases – all but one case
report was female patients. All cases complained of abdominal
pain and 24 reports documented increased cholestatic markers.
Other pathogens were not detected in any of the patients except in
one case with serological signs of CMV infection.8 The clinical
course did not differ in patients treated with antibiotics compared
with patients not receiving antibiotics. Only one patient had a
surgical procedure performed; all patients fully recovered. These
case reports indicate that treatment with antibiotics and surgery
might not be indicated nor necessary in uncomplicated cases of
AAC associated with primary EBV infection.
4.1. Comparison of the present and previous cases with previous
studies
In developing countries, 80 to 100% have serological signs of
EBV infection between three and six years of age. In developed
countries primary EBV infection is common in adolescents and
adults (between 10 and 30 years of age). EBV persists for life in
memory B cells in 90%; and may be passed to other individuals
through asymptomatic shedding. The incubation period is
between two and seven weeks.1,28,29 After one or two weeks of
fatigue, malaise, muscle pain, sweating and headache; the classic
symptoms of IM may develop with fever, pharyngitis and
lymphadenopathy. Other typical symptoms and signs are tonsillar
enlargement with thick exudate, fever (37.5-408C) for one to two
weeks, periorbital oedema, nasal congestion, palatal petecciae
(25%), splenomegaly ( 50%), hepatomegaly (30-50%) and rash (5%,
90-100% in cases treated with ampicillin). Cervical and generalised
adenopathy may be absent in patients above 40 years of age.1,28
Lymphocytosis is common (70%), atypical lymphocytosis (
10%) and monocytosis may indicate atypical lymphocytes. Liver
enzymes may be transient and moderately increased and
hyperbilirubinemia occurs (5% develop jaundice).2 Transient
neutropenia, thrombocytopenia and hemolytic anaemia may be
seen.1
Primary EBV may be complicated by prolonged malaise and
fever (<5%), upper airway obstruction, and in rare cases
encephalitis, cranial nerve palsies, peritonsillar abscess, myocar-
ditis or pleural effusion have been described. Hepatitis is often
described as a complication of EBV infection.1,2
AAC comprises 5-10% of acute cholecystitis, and is usually more
severe than acute calculous colecystitis (ACC). AAC can be caused
by severe infections (sepsis, typhoid fever, gastroenteritis (cholera,
Shigella, Giardia), pneumonia (Mycoplasma), late HIV), trauma,
surgery or systemic diseases.3 Viral etiology is rare, but since
1984 AAC has been known to occur in viral hepatitis.30,31
Table 1
Characteristics of previous5–27 and present cases with primary EBV and AAC.
Patient nr., author, year Age
(years),
sex
Country
(acquired
in)
Sore
throat
Abdominal
symptoms
Tempe-
rature
Pharyn-
gitis
Lymph-
adeno-
pathy
Murphy’s
sign
positive
Hepato-
spleno-
megaly
ALT
U/l6
Total
bilirubin6
ALP
(U/l) 6
WBC Lympho-
/mono-
cytes,%
CRP
mg/l
Gall
bladder
wall
Anti-
biotics
Sur-
gery
Days of
admis-
sion
1. Yoshie et al., 2004 15
Female
Japan Yes Yesf Fever - Yes Yes Spleno-
megaly
215 - 569 11 73 - 10 mm No No -
2. Prassouli et al., 2007 13
Female
Greece - Yesf 39.6 8C Yes Noe Yes - 674
(5-45)
4
mg/dl
721
(<248)
14 53/12 37
(<10)
13.6 mm Yes No 14
3. Lagona et al., 2007 4
Female
Greece - Yesf Fever Yes Yes Yes Yes 304
(5-45)
4.6
mg/dl
236
(38-148)
22 (25
atypical)
8
(0-5)
9 mm No No 13
4. Koch et al., 2007 53
Female
Nether-
lands
- Yesf 38 8C - - - - 339
(15-45)
120 (0-17)
mmol/l
1081
(40-120)
- - - 10 mm No No -
5. Gora Gebca et al, 2008 4
Female
Poland - Yesf Fever - - - Yes 423 2.9
mg/dl
752 26 22 (62
atypical)
18.8 7 mm Yes No -
6. Gora Gebca et al, 2008 9
Femalea
Poland - Yesf Fever Yes Yes Yes Yes 179 4.7
mg/dl
629 21 44/2.4 47.3 9 mm Yes No -
7. Iaria et al, 2007 18
Female
Italy Yes Yes 39 8C Yes Yes Yes Yes 328
(5-45)
7 (0.1-1.9)
mg/dl
312
(38-148)
22 70 6.5
(0-5)
9 mm Yes No 7
8. Pellicia et al., 2008 14
Female
Italy - Yesf Fever Yes Yes Yes Yes 108 - 358 - 72 - 10 mm No No -
9. Attilakos et al., 2009 5
Maleb
Greece Yes Yes Fever Yes Yes Yes Yes 257
(5-45)
1.8
mg/dl
919
(38-148)
23 (10
atypical)
13
(0-5)
4.2 mm No No 7
10. Hagel, 2009 21
Femalec
Germany - Flank
painf
40.5 8C - - Yes Spleno-
megaly
- 254
mmol/l
- 1.2 - 62 7 mm Yes Yes 19
11. Cholongitas et al, 2009 19
Female
Greece Yes Yesf 38 8C Yes Yes Yes - 584 6.5
mg/dl
710 14 55 35 8 mm No No 6
12. Yang et al., 2009 20
Female
Korea Yes Yes 38.3 8C Yes Yes Yes Yes 299 0.7
mg/dl
727 10 70 - Diffuse
oedema
Yes No 7
13. Chalupa et al., 2009 22
Female
Czech
Republic
- Yesf 40 8C Yes Yes Yes Yes 12.7
(0-0.8)
mkat/l
143
(0-20)
mmol/l
2.2
(0.5-2.0)
mkat/l
- 56/14
(14 atypical)
56.4
(0-8)
6 mm Yes No 19
14. Arya et al., 2010 16
Female
USA Yes Yesf 39 8C Yes Noe Yes No 211 8.5
mg/dl
458 26 81/8 - 9 mm Yes No 7
15. Beltrame et al, 2012 29
Female
Italy - Yesf - Yes Yes Yes - 166
(10-35)
23.2
(1.7-17)
mmol/l
161
(53-151)
? 51 14.4
(0-6)
15 mm Yes No 6
16. Nagdev et al, 2012 18
Femaled
Califor-
nia
No Yesf 99.7 8F No No RUQ
tenderness
- - 1.2 mg/dl 146 10.4 - - >10 mm Yes No 5
17. Dylewski, 2012 22
Female
Canada - Yesf 39 8C No Noe RUQ
tenderness
Spleno-
megaly
89
(5-60)
Normal - 5 49/10
(20 atypical)
- 5 mm Yes No -
18. Carrascosa et al., 2012 22
Female
Spain - Yesf Fever - Noe RUQ
tenderness
Yes 464 43mmol/l 239 9 61 - 14 mm No No 6
19. Aydin et al., 2013g 7
Female
Turkey - Yesf Fever Yes Yes RUQ
tenderness
Yes 496
(0-39)
4.6 mg/dl 434
(118-369)
10 71 - Marked
thickened
No No -
20. Poddighe et al., 2014 7
Female
Italyh - Yesf 37.4 8C Yes No Yes Hepato-
megaly
3324
(0-45)
11 (0.3-1.2)
mg/dl
- 9 - 3.5
(0-5)
10 mm Yes No 9
21. Gagneux-Brunon et al., 2014 18
Female
France - Yesf 38.5 8C No Yes Yes No 214 20mmol/l 165 6 30/28 - 12 mm Yes No 8
22. Gagneux-Brunon et al., 2014 20
Female
France - Yesf 38.5 8C Noi Yes RUQ t
enderness
No 494 38mmol/l 133 12 42/38 - 16 mm Yes No 5
23. Kim et al., 2014 10
Female
Korea - Yesf Fever No Yes Yes No 489 1 mg/dl - 8 56/12 4 6 mm Yes No 7
24. Suga et al., 2014 6
Female
Japan - Yesf 37.3 8C Yes Yes Yes No 139 0.4 mg/dl 506 13 (8 atypical) 6 4.6 mm Yes No 8
25. Fretzayas et al., 2014 11
Female
Greece - Yes Fever Yes Yes Yes Yes 198 31mmol/l 536 15 70/15 5 7.3 mm - No -
26. Fretzayas et al., 2014 12
Female
Greece - Yesf 38.5 8C No No - Yes 195 - - 5 53/9 11 9 - No 8
27. Present case 34
Female
Denmark
(Burkina
Faso)
No Yes 39 8C Yes Noe RUQ
tenderness
No 61
(10-45)
42 (5-25)
mmol/l
737
(35-105)
12.6 60/20 64.9
(<8)
11.3 mm Yes No 9
(): Normal values only reportedwhen described in the case report, -: Missing information, ?: 3960*109/l was reported, RUQ: right upper quadrant, ALT: alanine aminotransferase, ALP: alkaline phosphatase, a) Serological EBV and CMV infection, b) Gilberts syndrome, c)
Treated with azathioprine (ulcerative colitis), d) Hypothyreodism, e) Lymphadenopathy developed during hospital stay, f) Referred to hospital with abdominal pain, g) Serology indicated reactivation, h) Born in Parkistan, i) Tonsillopharyngitis 7 days previously.
J.
 A
g
erg
a
a
rd
,
 C
.S.
 La
rsen
 /
 In
tern
a
tio
n
a
l
 Jo
u
rn
a
l
 o
f
 In
fectio
u
s
 D
isea
ses
 3
5
 (2
0
1
5
)
 6
7
–
7
2
7
0
J. Agergaard, C.S. Larsen / International Journal of Infectious Diseases 35 (2015) 67–72 71The incubation period and clinical course of the case presented
here were compatible with primary EBV infection. The patient
had travelled to Burkina Faso one month prior to admission. She
was exposed to child(ren) in a country where most children
acquire primary EBV early in life. The patient experienced a
prodromal period and, although she did not present typical
symptoms of primary EBV on admission, more classic symptoms
developed during hospitalisation (pharyngitis, lymphadenopa-
thy, periorbital oedema and pleural effusion). Laboratory
analyses showed lymphocytosis, monocytosis, slightly elevated
ALT and cholestatic markers. Transient haemolytic anaemia and
thrombocytopenia occurred. The patient developed right upper
quadrant tenderness and fulﬁlled the criteria for AAC with a
marked thickening of the gallbladder wall (11.3 mm). Several
pathogen speciﬁc diagnostic tests performed were negative, and
primary EBV infection was conﬁrmed by seroconversion. Bacte-
rial cultures were negative. CRP dropped before initiation of
antibiotic treatment (Figure 1A).
In 22 of 26 previously reported cases abdominal pain was the
reason for referral to hospital and general lymphadenopathy
was not always present at admission (and did not always
develop).5–27 Thus, not only might signs of EBV with abdominal
pain raise the suspicion of AAC, but also signs of AAC without
severe illness should cause doctors to consider EBV as a possible
diagnosis.
We did not ﬁnd clinical, biochemical or USS signs of more or less
severe illness in patients not receiving antibiotics, and the
prognosis did not seem to depend on antibiotic treatment. Patients
with AAC due to bacterial infections can be severely ill and should
receive antibiotics, and gallbladder percutaneous drainage should
be performed.3 We did not ﬁnd any data on clinical or biochemical
markers which could support not treating patients with AAC with
antibiotics. Currently, it seems to be the doctor’s clinical
judgement that decides whether or not to initiate treatment.5–27
Corticosteroids may be used in primary EBV.32 In one case
corticosteroid treatment was reported. This patient had a
complicated course before the use of corticosteroids11 and we
are not able to conclude whether corticosteroids should be avoided
in AAC in primary EBV infection.
4.2. Pathogenesis
Cholestasis, increased bile viscosity, ischemia and secondary
infections were described as contributing factors to the pathogen-
esis of AAC.3 In hepatitis A direct viral invasion of the gallbladder
has been documented.33
Bile stasis was slight or moderate in this and previous cases,
blood circulation was not compromised and inﬂammatory markers
were only slightly elevated.5–27 These observations may point to
direct viral invasion. However, EBV is known to infect oral
epithelial cells, but direct invasion of the gallbladder wall has not
been described. EBV was not found by in situ hybridization of a
gallbladder removed due to hydrops in EBV infection.34
Interestingly, eicosanoid proinﬂammatory mediators play an
important role in AAC and eicosanoid synthesis depends on gender
(estrogen levels).35 Twenty-six of 27 patients with AAC in EBV
infection were female. However, AAC following surgery is reported
to be more frequent in male patients.3 A possible predisposition in
Gilbert’s Syndrome (GS) is discussed by Attilakos.10 The bilirubin
uridine glucurodyltransferase, which is a defect in GS, is involved
in glucuronidation of certain eicosanoids.36 Thus, data point to a
hypothetical genetic and/or gender predisposition for AAC in
primary EBV infection. Most reported cases were from Europe, but
this may be explained merely by the awareness and the
accessibility to USS examination rather than by a genetic
predisposition.4.3. Awareness of the link between AAC and EBV
Whether high bilirubin levels and a possible genetic and/or
gender predisposition is the cause of AAC or whether a high
bilirubin level could be one of the reasons for performing the USS,
discovering a thickened gallbladder wall, is not possible to
determine from the 27 reported cases. In 2001, Yamada reviewed
USSs of 39 patients with mononucleosis syndrome. Six had a
gallbladder wall thickness above 3 mm and these six patients did
not differ in bilirubin or ALP levels from patients with gallbladder
wall thickness below 3 mm.37 In these patients bilirubin levels
would not have guided which patients to suspect for AAC.
Furthermore, in Yamada’s review four of six patients with
gallbladder wall thickness above 3 mm were female, whereas
18 of the 33 patients without gallbladder wall thickening were
male.37
Our and previous cases were reported from developed countries
with easy access to USS; this may indicate that AAC could be just as
prevalent in primary EBV infection in other parts of the world.
Currently, our health care system focuses on fast track diagnoses
and scanning opportunities become more and more accessible. USS
or CT scans may be performed more frequently, before results of
monospot or EBV serology, in patients with uncomplicated
primary EBV admitted to hospital with abdominal pain. The
prevalence of a thickened gallbladder wall in primary EBV with or
without cholestasis is unknown. A more frequent use of USS might
lead to diagnosis of more patients with AAC. Knowledge of a
possible uneventful recovery without antibiotics or surgery is thus
increasingly important. On the other hand, these data also show
that EBV infection with AAC may present with abdominal pain.
Therefore surgeons should be aware of possible EBV infection, and
order EBV antibody titers, in patients with AAC without another
obvious cause, especially in young female patients.
Twenty-seven cases of AAC in primary EBV infection have been
reported since 2003, all but one in female patients. It seems that
surgical drainage is not necessary and future cases may help to
clarify whether antibiotic treatment should be avoided. Possible
AAC in primary EBV infection is important to consider for both
medical physicians and surgeons.
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